✦ LIBER ✦

6519 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials

✍ Scribed by Llovet, J.; Cheng, A.; Qin, S.; Shan, M.; Nadel, A.; Burock, K.; Forner, A.; Zou, J.; Bruix, J.

Book ID: 122798944
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 47 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71241-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial

✍ Ann-Lii Cheng; Zhongzhen Guan; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Su 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 553 KB

823 IMPACT OF PRIOR TACE/TAE ON THE EFFI

823 IMPACT OF PRIOR TACE/TAE ON THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FROM THE ASIA-PACIFIC REGION

✍ W.Y. Tak; S. Yu; C.J. Tsao; T.S. Yang; J.S. Kim; S. Qin; K. Burock; J. Zou; D. V 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

## Background: Most cases of hepatocellular carcinoma occur in the asia-pacific region, where chronic hepatitis b infection is an important aetiological factor. assessing the efficacy and safety of new therapeutic options in an asia-pacific population is thus important. we did a multinational phase